Fielmann Group AG/€FIE

1D1W1MYTD1Y5YMAX

About Fielmann Group AG

Fielmann Group AG operates in the eyewear industry, providing optical products and services predominantly in Europe. The company is engaged in the retail of eyeglasses, contact lenses, hearing aids, and various accessories through a widespread network of stores. Headquartered in Hamburg, Germany, Fielmann was founded in 1972 by Günther Fielmann, who started with a single optical shop. The company's strategic positioning is enhanced by its direct relationship with end consumers and manufacturer-like operations, allowing it to offer competitively priced products without compromising quality. Fielmann's extensive market presence and customer-centric approach have contributed to its substantial growth across multiple European markets.
Ticker
€FIE
Primary listing
XETRA
Employees
18,571
Headquarters
Hamburg, Germany

FIE Metrics

BasicAdvanced
€3.2B
15.35
€2.48
0.61
€1.40
3.68%

Bulls say / Bears say

International growth is gaining momentum. Constant-currency growth outside Germany accelerated from 1% in the first quarter to 6% in the second, led by Spain and Poland, while US growth reached 4.5% in the second quarter. (Vision Monday, EQS News)
Profitability has held up despite modest top-line growth. First-half adjusted EBITDA rose to about €296m from €292m, while the adjusted EBITDA margin remained around 24%, showing that cost discipline is cushioning weaker demand. (Vision Monday, EQS News)
Fielmann is expanding its capacity for future growth, with 37 new locations added in the first half and a further 33 planned for the second half. AI-enabled refraction technology is also being rolled out to 300 European stores by year-end, which could lift productivity and improve customer access. (Webdisclosure, EQS News)
Germany still generates around 60% of group sales, and weak consumer sentiment there has forced Fielmann to cut its 2026 sales outlook to €2.50bn–€2.55bn from €2.55bn–€2.60bn. That leaves the business exposed to a prolonged slowdown in its largest market. (Börsen-Zeitung, EQS News)
The lower sales outlook is also feeding through to earnings: 2026 adjusted EBITDA guidance has fallen to €560m–€580m from €590m–€610m, while the expected EBITDA margin has been reduced to 22%–23%. This suggests weaker demand and ongoing investment will limit near-term operating leverage. (EQS News, MarketScreener)
The international diversification plan is not yet large enough to remove execution risk: group sales rose only 2% in the first half, while US sales increased 3.3% at constant currency and still required investment in the platform and doctor capacity. Fielmann is therefore relying on a stronger second half to make the expansion case work. (Vision Monday, EQS News)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.